Difference between revisions of "Sutimlimab (Enjaymo)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Anti-C1s antibodies]] | [[Category:Anti-C1s antibodies]] | ||
| + | |||
| + | [[Category:Cold agglutinin disease medications (investigational)]] | ||
| + | |||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 20:41, 29 April 2022
Mechanism of action
Anti-C1s antibody
Preliminary data
Cold agglutinin disease
- CARDINAL: Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. link to original article PubMed NCT03347396
Also known as
- Code name: BIVV009